Biogen Idec Inc. may have missed its earnings estimates by a penny, but that news was trumped by growing revenues from multiple sclerosis (MS) drug Tysabri (natalizumab), which jumped 28 percent over last year largely due to the availability of a JC virus assay to manage risk for progressive multifocal leukoencephalopathy (PML).